Top

Published in:

01-01-2007 | ORIGINAL COMMUNICATION

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS)

A comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

Authors: Volker Limmroth, MD, PhD, Rolf Malessa, MD, PhD, Uwe Klaus Zettl, MD, PhD, Jürgen Koehler, MD, PhD, Gudrun Japp, MD, Peter Haller, MD, PhD, Wolfgang Elias, MD, Winfried Obhof, MD, Andrea Viehöver, MD, Uwe Meier, MD, Arne Brosig, MD, Joerg Hasford, MD, PhD, Norman Putzki, MD, Gabriele Kalski, PhD, Colin Wernsdörfer, MD, for the QUASIMS Study Group

Published in: Journal of Neurology | Issue 1/2007

Abstract

Interferon beta (IFNβ) preparations are the most frequently prescribed therapies for patients with relapsing multiple sclerosis (MS). Several open-label observational studies report similar efficacy among IFNβ preparations. The Quality Assessment in Multiple Sclerosis Therapy (QUASIMS) study is a large, open-label observational study designed to compare the effectiveness and tolerability of available IFNβ preparations as disease-modifying therapies for relapsing MS across a wide range of clinical practice settings. This retrospective, controlled cohort study was conducted by chart review at 510 sites in Germany, Austria, and Switzerland. Enrolled patients had received one of the four available IFNβ preparations/dosing regimens (intramuscular IFNβ-1a 30 µg 1×/week [Avonex^®], subcutaneous (SC) IFNβ-1a 22 or 44 µg 3×/week [Rebif^®], or SC IFNβ-1b 250 µg 3.5×/week [Betaferon/Betaseron^®]) for ≥ 2 years. Preplanned outcomes at 1 and 2 years included change from baseline Expanded Disability Status Scale (EDSS) score, percentage of progression-free patients (< 1.0 EDSS point), annualised relapse rate (RR), percentage of relapse-free patients, and reasons for therapy change. Of 4754 evaluable patients, 3991 (84%) received IFNβ as initial therapy. There were no significant differences among IFNβs when used as initial or follow-up therapy on almost all outcome variables. Relapse rate was consistently higher and percentage of relapse-free patients consistently lower for all products used as follow-up versus initial therapy. Results of QUASIMS showed similar effectiveness among IFNβ products. Benefits were consistently superior when IFNβ was used as initial rather than follow-up therapy. Our results suggest that patients do not benefit in terms of disease outcome from switching between IFNβ preparations/dosing regimens.

Durelli L, Verdun E, Barbero P, et al. (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453–1460PubMedCrossRef

Haas J, Firzlaff M, Schmidt M (2005) Twenty-four-month comparison of immunomodulatory agents – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate. Eur J Neurol 12:425–431PubMedCrossRef

The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta 1-b: experience during the first three years. Neurology 47:889–894

The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277–2385

IMS^® Xponent, IMS Health GmbH & Co. OHG, 02/2004

Jacobs LD, Cookfair DL, Rudick RA, et al. and the Multiple Sclerosis Collaborative Research Group (MSCRG) (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–294PubMedCrossRef

Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology 33:1444–1452PubMed

Li DKB, Paty DW, the UBC MS/MRI Analysis Research Group, and the PRISMS Study Group (1999) Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 46:197–206PubMedCrossRef

10.

Limmroth V, Putzki N (2005) High dose, frequently administered interferon beta. J Neurol Sci 231:95–96PubMedCrossRef

11.

Milanese C, La Mantia L, Palumbo R, the North Italy Multiple Sclerosis Group (2003) A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 74:1689–1692PubMedCrossRef

12.

Miralles AA, Fuentes B, Barreiro P, Diez-Tejedor E (2000) Comparative clinical efficacy analysis between interferon beta 1-b and interferon beta 1-a. J Neurol 247:III139 Abstract

13.

Öztekin N, Öztekin MF (2001) An open-label trial comparing the effects of IFNβ-1a (Rebif), (Avonex), and IFNβ-1b (Betaferon) on the relapse rate, lesion load on MRI and disease progression in patients with relapsing-remitting multiple sclerosis: results of 24 months of therapy. Mult Scler 7:S96 Abstract

14.

Pakdaman H (2001) Response to beta-interferon in Iranian multiple sclerosis patients. Mult Scler 17:S54 Abstract

15.

Palace J (2003) Comparative study of IFN beta-1a 44 mcg tiw and 30 mcg qw: final EVIDENCE results. Mult Scler 9(Suppl 1):S24 Abstract

16.

Panitch H, Goodin DS, Francis G, et al. for the EVIDENCE Study Group and the University of British Columbia MS/MRI Research Group (2002) Randomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE trial. Neurology 59:1496–1506PubMed

17.

Paty DW, Li DK, the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:662–667PubMed

18.

Poser CM, Paty DW, Scheinberg L, et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231PubMedCrossRef

19.

PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504CrossRef

20.

The PRISMS (Prevention of Relapses, Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group, and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4. Long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56:1628–1636

21.

Rebif [prescribing information] (2004) Ares-Serono, Geneva, Switzerland

22.

Río J, Tintoré M, Nos C, Téllez N, Galán I, Montalban X (2005) Interferon beta in relapsing-remitting multiple sclerosis – an eight years experience in a specialist multiple sclerosis center. J Neurol 252:795–800PubMedCrossRef

23.

Seijo-Martinez M, Amigo MC, Arias M, et al. (2001) Experience of interferon beta (INF-β) treatment in relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS) in Galicia (Spain). Mult Scler 7:S54 Abstract

24.

Simon JH, Jacobs LD, Campion M, et al. and the Multiple Sclerosis Collaborative Research Group (MSCRG) (1998) Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol 43:79–87PubMedCrossRef

25.

Simon JH, Lull J, Jacobs LD, et al. and the Multiple Sclerosis Collaborative Research Group (MSCRG) (2000) A longitudinal study of T1 hypointense lesions in relapsing MS. MSCRG trial of interferon β-1a. Neurology 55:185–192PubMed

26.

Trojano M, Liguori M, Paolicelli D, et al. (2003) Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 9:451–457PubMedCrossRef

27.

Koch-Henriksen N, Sorensen PS, Christensen T, et al. (2006) A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 66:1056–60PubMedCrossRef

Title: Quality Assessment in Multiple Sclerosis Therapy (QUASIMS)
A comparison of interferon beta therapies for relapsing-remitting multiple sclerosis
Authors: Volker Limmroth, MD, PhD
Rolf Malessa, MD, PhD
Uwe Klaus Zettl, MD, PhD
Jürgen Koehler, MD, PhD
Gudrun Japp, MD
Peter Haller, MD, PhD
Wolfgang Elias, MD
Winfried Obhof, MD
Andrea Viehöver, MD
Uwe Meier, MD
Arne Brosig, MD
Joerg Hasford, MD, PhD
Norman Putzki, MD
Gabriele Kalski, PhD
Colin Wernsdörfer, MD
for the QUASIMS Study Group
Publication date: 01-01-2007
Publisher: Steinkopff-Verlag
Published in: Journal of Neurology / Issue 1/2007
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-006-0281-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS)

A comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2007

Movement disorder due to aceruloplasminemia and incorrect diagnosis of hereditary hemochromatosis

A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis

Does modafinil enhance activity of patients with myotonic dystrophy?

Interaction between prion protein and interleukin-1A genes increases early-onset Alzheimer’s disease risk

Upbeat nystagmus due to a caudal medullary lesion and influenced by gravity

The effect of age of onset of PD on risk of dementia